This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Also, we look at a published report on the real-world efficacy of the COVID-19 treatment remdesivir.